· Laquinimod ― Phase III trials proceeding as planned
· TASQ ― final Phase II data presented at ASCO. Phase III preparations proceeding on schedule
· ANYARA ― article published in Journal of Immunotherapy
· 57-57 ― exploratory clinical trial under way. Development for treatment of orphan drug indication (systemic sclerosis/scleroderma) initiated
· ISI ― project continuing according to plan
· RhuDex(TM) ― preclinical studies completed during the year
· Net sales of SEK 6.1 M (5.2)
· Operating loss of SEK 102.4 M (loss: 118.5)
· Loss after tax SEK 108.3 M (loss: 118.6)
· Loss per share for the period amounted to SEK 1.67 (loss: 2.22)
· The company received approximately SEK 149 M from a directed share issue, cash and cash equivalents at the end of the period amounted to SEK 235 M
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam
CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
